Literature DB >> 30030380

The effect of truncation on prion-like properties of α-synuclein.

Makoto Terada1,2, Genjiro Suzuki3, Takashi Nonaka3, Fuyuki Kametani3, Akira Tamaoka2, Masato Hasegawa4.   

Abstract

Increasing evidence suggests that α-synuclein (αS) aggregates in brains of individuals with Parkinson's disease and dementia with Lewy bodies can spread in a prion-like manner. Although the initial αS nuclei are pivotal in determining αS fibril polymorphs and resulting phenotypes, it is not clear how the initial fibril seeds are generated. Previous studies have shown that αS truncation might have an important role in αS aggregation. However, little is known about how this truncation influences αS's propagation properties. In the present study, we generated αS fibrils from a series of truncated human αS constructs, characterized their structures and conformational stabilities, and investigated their ability to convert the conformation of full-length αS in vitro, in cultured cells, and in WT mice. We show that both C- and N-terminal truncations of human αS induce fibril polymorphs and exhibit different cross-seeding activities. N-terminally 10- or 30-residue-truncated human αS fibrils induced more abundant αS pathologies than WT fibrils in mice, whereas other truncated fibrils induced less abundant pathologies. Biochemical analyses of these truncated fibrils revealed that N-terminal 10- or 30-residue truncations of human αS change the fibril conformation in a manner that increases their structural compatibility with WT mouse αS fibrils and reduces their stability. C-terminally 20-residue-truncated fibrils displayed enhanced seeding activity in vitro Our findings imply that truncation of αS can influence its prion-like pathogenicity, resulting in phenotypic diversity of α-synucleinopathies.
© 2018 Terada et al.

Entities:  

Keywords:  Parkinson's disease; Western blot; alpha-synuclein (a-synuclein); amyloid; electron microscopy (EM); fibril; immunohistochemistry; neurodegeneration; neurodegenerative disease; polymorphs; prion; prion-like; protein aggregation; protein structure; protein truncation; truncation

Mesh:

Substances:

Year:  2018        PMID: 30030380      PMCID: PMC6130941          DOI: 10.1074/jbc.RA118.001862

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  73 in total

1.  Impact of the acidic C-terminal region comprising amino acids 109-140 on alpha-synuclein aggregation in vitro.

Authors:  Wolfgang Hoyer; Dmitry Cherny; Vinod Subramaniam; Thomas M Jovin
Journal:  Biochemistry       Date:  2004-12-28       Impact factor: 3.162

2.  α-Synuclein strains cause distinct synucleinopathies after local and systemic administration.

Authors:  W Peelaerts; L Bousset; A Van der Perren; A Moskalyuk; R Pulizzi; M Giugliano; C Van den Haute; R Melki; V Baekelandt
Journal:  Nature       Date:  2015-06-10       Impact factor: 49.962

3.  Molecular analysis and biochemical classification of TDP-43 proteinopathy.

Authors:  Hiroshi Tsuji; Tetsuaki Arai; Fuyuki Kametani; Takashi Nonaka; Makiko Yamashita; Masami Suzukake; Masato Hosokawa; Mari Yoshida; Hiroyuki Hatsuta; Masaki Takao; Yuko Saito; Shigeo Murayama; Haruhiko Akiyama; Masato Hasegawa; David M A Mann; Akira Tamaoka
Journal:  Brain       Date:  2012-10-03       Impact factor: 13.501

Review 4.  The role of protein clearance mechanisms in organismal ageing and age-related diseases.

Authors:  David Vilchez; Isabel Saez; Andrew Dillin
Journal:  Nat Commun       Date:  2014-12-08       Impact factor: 14.919

5.  Identification of two distinct synucleins from human brain.

Authors:  R Jakes; M G Spillantini; M Goedert
Journal:  FEBS Lett       Date:  1994-05-23       Impact factor: 4.124

6.  Exogenous alpha-synuclein fibrils seed the formation of Lewy body-like intracellular inclusions in cultured cells.

Authors:  Kelvin C Luk; Cheng Song; Patrick O'Brien; Anna Stieber; Jonathan R Branch; Kurt R Brunden; John Q Trojanowski; Virginia M-Y Lee
Journal:  Proc Natl Acad Sci U S A       Date:  2009-11-05       Impact factor: 11.205

7.  α-Synuclein Fibrils Exhibit Gain of Toxic Function, Promoting Tau Aggregation and Inhibiting Microtubule Assembly.

Authors:  Takayuki Oikawa; Takashi Nonaka; Makoto Terada; Akira Tamaoka; Shin-Ichi Hisanaga; Masato Hasegawa
Journal:  J Biol Chem       Date:  2016-05-19       Impact factor: 5.157

Review 8.  Protein Transmission, Seeding and Degradation: Key Steps for α-Synuclein Prion-Like Propagation.

Authors:  Abid Oueslati; Methodios Ximerakis; Kostas Vekrellis
Journal:  Exp Neurobiol       Date:  2014-12-12       Impact factor: 3.261

9.  Solution conditions determine the relative importance of nucleation and growth processes in α-synuclein aggregation.

Authors:  Alexander K Buell; Céline Galvagnion; Ricardo Gaspar; Emma Sparr; Michele Vendruscolo; Tuomas P J Knowles; Sara Linse; Christopher M Dobson
Journal:  Proc Natl Acad Sci U S A       Date:  2014-05-09       Impact factor: 11.205

10.  Structural and functional characterization of two alpha-synuclein strains.

Authors:  Luc Bousset; Laura Pieri; Gemma Ruiz-Arlandis; Julia Gath; Poul Henning Jensen; Birgit Habenstein; Karine Madiona; Vincent Olieric; Anja Böckmann; Beat H Meier; Ronald Melki
Journal:  Nat Commun       Date:  2013       Impact factor: 14.919

View more
  33 in total

1.  Physiological C-terminal truncation of α-synuclein potentiates the prion-like formation of pathological inclusions.

Authors:  Zachary A Sorrentino; Niran Vijayaraghavan; Kimberly-Marie Gorion; Cara J Riffe; Kevin H Strang; Jason Caldwell; Benoit I Giasson
Journal:  J Biol Chem       Date:  2018-10-16       Impact factor: 5.157

Review 2.  The emerging role of α-synuclein truncation in aggregation and disease.

Authors:  Zachary A Sorrentino; Benoit I Giasson
Journal:  J Biol Chem       Date:  2020-05-18       Impact factor: 5.157

3.  Carboxy-terminal truncations of mouse α-synuclein alter aggregation and prion-like seeding.

Authors:  Zachary A Sorrentino; Yuxing Xia; Kimberly-Marie Gorion; Ethan Hass; Benoit I Giasson
Journal:  FEBS Lett       Date:  2020-01-24       Impact factor: 4.124

4.  Cathepsin K is a potent disaggregase of α-synuclein fibrils.

Authors:  Ryan P McGlinchey; Shannon M Lacy; Robert L Walker; Jennifer C Lee
Journal:  Biochem Biophys Res Commun       Date:  2020-07-31       Impact factor: 3.575

5.  The vermiform appendix impacts the risk of developing Parkinson's disease.

Authors:  Bryan A Killinger; Zachary Madaj; Jacek W Sikora; Nolwen Rey; Alec J Haas; Yamini Vepa; Daniel Lindqvist; Honglei Chen; Paul M Thomas; Patrik Brundin; Lena Brundin; Viviane Labrie
Journal:  Sci Transl Med       Date:  2018-10-31       Impact factor: 17.956

6.  NMR unveils an N-terminal interaction interface on acetylated-α-synuclein monomers for recruitment to fibrils.

Authors:  Xue Yang; Baifan Wang; Cody L Hoop; Jonathan K Williams; Jean Baum
Journal:  Proc Natl Acad Sci U S A       Date:  2021-05-04       Impact factor: 11.205

Review 7.  Mechanisms of Strain Diversity of Disease-Associated in-Register Parallel β-Sheet Amyloids and Implications About Prion Strains.

Authors:  Yuzuru Taguchi; Hiroki Otaki; Noriyuki Nishida
Journal:  Viruses       Date:  2019-01-28       Impact factor: 5.048

8.  Carboxy-terminal truncation and phosphorylation of α-synuclein elongates survival in a prion-like seeding mouse model of synucleinopathy.

Authors:  Zachary A Sorrentino; Ethan Hass; Niran Vijayaraghavan; Kimberly-Marie Gorion; Cara J Riffe; Jess-Karan S Dhillon; Benoit I Giasson
Journal:  Neurosci Lett       Date:  2020-05-01       Impact factor: 3.046

Review 9.  Lipids: Key Players That Modulate α-Synuclein Toxicity and Neurodegeneration in Parkinson's Disease.

Authors:  Akio Mori; Yuzuru Imai; Nobutaka Hattori
Journal:  Int J Mol Sci       Date:  2020-05-07       Impact factor: 5.923

Review 10.  Alpha-Synuclein Post-translational Modifications: Implications for Pathogenesis of Lewy Body Disorders.

Authors:  Nelson de Oliveira Manzanza; Lucia Sedlackova; Raj N Kalaria
Journal:  Front Aging Neurosci       Date:  2021-06-25       Impact factor: 5.750

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.